Janux Therapeutics, Inc. Share Price & Technical Analysis
JANX · $14.52 (+0.76%)
Healthcare / Biotechnology
$14.52
+0.76%
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, -19% avg return in past 3 year May month.
8% return in 2026, 143% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 0% | 5% | 2% | 2% | – | – | – | – | – | – | – | 8% |
| 25 | -20% | -22% | -17% | 23% | -27% | -4% | 4% | -5% | 7% | 19% | 22% | -59% | -78% |
| 24 | -20% | 456% | -16% | 52% | -6% | -23% | -3% | 18% | -3% | 19% | -17% | 19% | 476% |
| 23 | 67% | -25% | -27% | 26% | -25% | 3% | 21% | -21% | -9% | -36% | 34% | 22% | 30% |
| 22 | -22% | 13% | -20% | -31% | 14% | 10% | 2% | -11% | 27% | 32% | -25% | -4% | -14% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$880.61M
P/E ratio
—
52W high
$35.34
52W low
$12.12
Volume
4,36,399
Beta
2.57
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Janux Therapeutics, Inc. share price today?
- Janux Therapeutics, Inc. (JANX) last traded around $14.52 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does JANX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for JANX. Download the app for real-time alerts.
- How can I analyze Janux Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.